Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Summary

This is a multicenter, randomized, controlled, phase III study.

Timeline

Start

2020-10

Primary completion

2022-10

Completion

2023-10

Outcome

Met primary endpoint

paper combination therapy significantly prolonged median PFS compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). PMID 41818162 ↗

Publications

• Duan JC, Zhong J, Sun BY, Zhao WH, Wu L, Fei KL, Chu Q, Guo QS, Song QB, Yu Y, Zhu DX, Liu XY, Zhao J, Zhan ZX, Li S, Nie L, Lin J, Peng XD, Zhong DS, Zhou J, Li LH, Chen YF, Hu C, Mok T, Wang ZJ, Wang J. Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. CA Cancer J Clin. 2026 Mar-Apr;76(2):e70071. doi: 10.3322/caac.70071.

Drugs

Indications